Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CQCIH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD123A
|
|||||
| Synonyms |
SGN-CD123A
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
H7G3ec
|
Antibody Info | ||||
| Antigen Name |
Interleukin-3 receptor subunit alpha (IL3RA)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
talirine
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Acute myeloid leukaemia |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires CD123-positive AML patients with 1-3 prior regimens (high-risk cases may qualify after 1 regimen), adequate organ function and ECOG 0-1, excluding those with CNS involvement, promyelocytic leukemia, significant pulmonary dysfunction, recent transplants, or recent antileukemia/experimental treatments within 4 weeks (hydroxyurea/6-MP allowed).
Click to Show/Hide
|
||||
| Administration Dosage |
Intravenous infusion in 3-week cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02848248 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | ||||
| Primary Endpoint |
The primary safety endpoints assess adverse event profiles (type/incidence/severity/seriousness/relatedness) and lab abnormalities during treatment and 1-month post-treatment, along with dose-limiting toxicity incidence during the initial 3-week cycle.
|
||||
| Other Endpoint |
Secondary objectives include pharmacokinetic analysis (SGN-CD123A blood concentrations), immunogenicity (antitherapeutic antibodies), and efficacy measures (remission rate, complete remission duration, leukemia-free survival, and overall survival) monitored for approximately 1 year in relapsed/refractory AML patients.
|
||||